CJC-1295 No DAC vs Sermorelin: Research Comparison
CJC-1295 No DAC and sermorelin are both discussed in GH-axis research because they are connected to growth hormone-releasing hormone signaling. The key difference is that sermorelin has historical FDA approval as a drug product for a narrow pediatric indication, while CJC-1295 is an investigational analog with limited clinical data and no FDA-approved indication.
Compound-by-compound briefing
| Field | CJC-1295 No DAC | Sermorelin |
|---|---|---|
| Commonly researched for | Growth hormone signaling, GH pulse research, IGF-1 response, endocrine research, body composition research, and GH-axis physiology. | GH-axis testing, pediatric growth hormone deficiency history, pituitary stimulation, and endocrine research. |
| Mechanism of interest | A synthetic GHRH analog studied for stimulating pituitary growth hormone release through GHRH receptor activity. | A 29-amino-acid GHRH analog that stimulates pituitary growth hormone release through GHRH receptor signaling. |
| Evidence strength | Early to Moderate | Moderate |
| Human evidence | Limited. Human studies exist for CJC-1295, but it is not an FDA-approved drug and clinical data remain limited. | More established historically than CJC-1295. Sermorelin had FDA-approved drug status for a narrow pediatric growth hormone deficiency indication, but the commercial product was discontinued. |
| Preclinical evidence | Supports GH-axis mechanism and pituitary stimulation models, but translation depends on route, formulation, and clinical context. | Mechanistic rationale is based on GHRH physiology and pituitary stimulation. |
| Main caution | Not FDA-approved. FDA has flagged CJC-1295 in compounding-risk discussions, including limited clinical data and serious adverse events such as increased heart rate and systemic vasodilatory reaction. | The previously approved product is discontinued. Current compounded or research-use versions should not be treated as equivalent to an available FDA-approved commercial product. |
| Regulatory status | Not FDA-approved for any clinical indication. | Previously FDA-approved as Geref for pediatric growth hormone deficiency or growth failure. FDA later determined the product was not withdrawn for reasons of safety or effectiveness, but it is no longer commercially available as that approved product. |
- Commonly researched for
- Growth hormone signaling, GH pulse research, IGF-1 response, endocrine research, body composition research, and GH-axis physiology.
- Mechanism of interest
- A synthetic GHRH analog studied for stimulating pituitary growth hormone release through GHRH receptor activity.
- Evidence strength
- Early to Moderate
- Human evidence
- Limited. Human studies exist for CJC-1295, but it is not an FDA-approved drug and clinical data remain limited.
- Preclinical evidence
- Supports GH-axis mechanism and pituitary stimulation models, but translation depends on route, formulation, and clinical context.
- Main caution
- Not FDA-approved. FDA has flagged CJC-1295 in compounding-risk discussions, including limited clinical data and serious adverse events such as increased heart rate and systemic vasodilatory reaction.
- Regulatory status
- Not FDA-approved for any clinical indication.
- Commonly researched for
- GH-axis testing, pediatric growth hormone deficiency history, pituitary stimulation, and endocrine research.
- Mechanism of interest
- A 29-amino-acid GHRH analog that stimulates pituitary growth hormone release through GHRH receptor signaling.
- Evidence strength
- Moderate
- Human evidence
- More established historically than CJC-1295. Sermorelin had FDA-approved drug status for a narrow pediatric growth hormone deficiency indication, but the commercial product was discontinued.
- Preclinical evidence
- Mechanistic rationale is based on GHRH physiology and pituitary stimulation.
- Main caution
- The previously approved product is discontinued. Current compounded or research-use versions should not be treated as equivalent to an available FDA-approved commercial product.
- Regulatory status
- Previously FDA-approved as Geref for pediatric growth hormone deficiency or growth failure. FDA later determined the product was not withdrawn for reasons of safety or effectiveness, but it is no longer commercially available as that approved product.
Comparing Compounds? Read This First.
The Playbook helps you understand evidence quality, mechanism claims, safety limitations, and sourcing red flags before comparing research compounds.
Educational research only. No medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.
Plain-language difference
Sermorelin is closer to the original GHRH fragment concept and has a stronger historical clinical footing. CJC-1295 is a modified GHRH analog designed for extended or altered GH-axis activity depending on form. CJC-1295 No DAC is usually discussed as shorter acting than DAC forms, but it still should not be framed casually as a safer or proven alternative.
Mechanism comparison
Both compounds act upstream of growth hormone release by stimulating the pituitary through GHRH-related signaling. Sermorelin is the more classic GHRH analog. CJC-1295 is a modified analog built to influence GH and IGF-1 dynamics. The GH-axis distinction matters because these compounds do not replace growth hormone directly; they study or influence the body's own growth hormone release pathways.
Evidence comparison
Sermorelin has historical FDA-approved context for a narrow pediatric indication and a clearer clinical background. CJC-1295 has human studies showing GH and IGF-1 effects, but it remains investigational and has no FDA-approved indication. Neither should be represented as an anti-aging, muscle-building, fat-loss, or performance treatment.
Safety and regulatory context
GH-axis manipulation can intersect with glucose metabolism, fluid retention, cardiovascular issues, cancer biology concerns, and endocrine feedback loops. CJC-1295 deserves stricter caution because FDA has specifically identified safety concerns and limited clinical data. Sermorelin's historical approval does not automatically validate every current compounded or research-use product.
Continue down a research path
Full compound breakdowns
Research-Use-Only Sourcing Standards
Before evaluating any supplier, review the standards that matter: Certificate of Analysis access, batch transparency, purity testing, clear labeling, restrained claims, and research-use-only positioning.
- 01Certificate of Analysis available
- 02Batch or lot transparency
- 03Purity testing clearly stated
- 04Clear compound labeling
- 05No exaggerated medical claims
- 06Research-use-only language
- 07Supplier disclosure visible
Some supplier links may be affiliate links. Peptide Pressure may earn compensation. Affiliate relationships do not influence evidence grading, safety framing, or editorial standards.
Disclaimer: This page is for educational and research purposes only. It does not provide medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.